ClinicalTrials.gg
Enrolling by invitationNCT06374498Updated Nov 10, 2026

Study to Determine the Clinical Significance of Intravascular OCT-NIRAF

An interventional study of OCT-NIRAF and LUMISIGHT Injection in Cardiovascular Diseases and Coronary Artery Disease, sponsored by Massachusetts General Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Primary conditionCoronary Artery DiseaseRegistry: Cardiovascular DiseasesReclassifiedWhy we changed it
Registry
Cardiovascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Coronary Artery Disease
Why
  1. The study's listed conditions name Coronary Artery Disease, a narrower term within Cardiovascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Basic science

How we know

Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Coronary Artery Disease by Massachusetts General Hospital — 2 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · Massachusetts General Hospital.

Planned enrollment
7th of 14
70 · median 67
Started
2024
the only one that year
No phase
8 of 16
2 open now
Registered
15th of 16
by date

Among the 16 studies in Coronary Artery Disease by Massachusetts General Hospital, this one is the 7th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2024, is one of 8 with no phase, and was the 15th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

2 of the 16 studies in Coronary Artery Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Coronary Artery Disease by Massachusetts General Hospital, or all of them as a file.
02

Study summary

There are 2 arms to this study.

Arm 1: Participants undergoing coronary angiography for stable or acute coronary disease presentations and eligible for percutaneous coronary intervention (PCI) will be imaged with OCT-NIRAF at baseline and with CCTA 12 months apart to demonstrate that:

  1. NIRAF coronary artery signal level (patient, artery, lesion basis) is correlated with the severity of coronary artery disease.
  2. NIRAF coronary artery signal level is a predictor of plaque progression on a per participant, per artery, or per lesion basis.

Arm 2: Participants undergoing coronary angiography for stable or acute coronary disease presentations and eligible for percutaneous coronary intervention (PCI) will be imaged with OCT-NIRAF following injection of LUMISIGHT. The primary objective is to assess the feasibility of intravascular detection and spatial localization of LUMISIGHT during routine coronary imaging.

Read the detailed description

Arm 1:

This study will provide preliminary data on the clinical value of intracoronary OCT-NIRAF imaging in participants undergoing invasive coronary angiography in the cardiac catheterization laboratory. This is a single site, prospective feasibility study where 40 study subjects undergoing coronary angiography for stable or acute coronary disease presentations and eligible for percutaneous coronary intervention (PCI) will undergo intravascular imaging, including standard-of-care IVUS and then OCT-NIRAF pullback imaging conducted during an iodinated contrast flush. Patients will be consented prior to catheterization. Participant characteristics such as age, sex, BMI, and current medication regimen will be recorded. Standard of care blood chemistry will be reviewed and lab values from the subject's electronic medical records will be input into the study's Case Report Form when available. A complete medical history and data regarding prescribed cardiac medications also be transcribed from the EMR into the CRF.

Coronary Angiography will be performed. For participants for whom coronary angiography provides a clinical indication for intravascular imaging or PCI without any exclusion criteria, 40 study participants will undergo intravascular imaging, including standard-of-care IVUS and then research study OCT-NIRAF pullback imaging, conducted during an iodinated contrast flush.

Intravascular imaging of the PCI target artery will be done prior to PCI unless the interventional cardiologist determines that intervention is required to deliver the imaging catheters. The other major coronary arteries may also be imaged by IVUS and OCT-NIRAF based on clinical assessment of the appropriateness of imaging by the interventional cardiologist.

In addition, participants will obtain a baseline coronary CTA at MGH, using standard clinical protocols in the MGH Department of Radiology.

Follow up imaging: After 12 months (+/- 28 days), participants will undergo a follow-up study coronary CTA, to assess for plaque progression compared to the baseline coronary CTA.

Follow up: Participants will undergo standard-of-care cardiology follow-up and medical record review follow-up by study staff at 1 month (+/- 7 days), 6 months (+/- 28 days), and 1 year (+/- 28 days). After completion of the CCTA and final telephone 12-month follow-up, patients will be released from the study.

Arm 2:

This study will provide preliminary data on the clinical value of intracoronary OCT-NIRAF imaging following LUMISIGHT injection in participants undergoing invasive coronary angiography in the cardiac catheterization laboratory. This is a single site, prospective feasibility study where 30 study subjects undergoing coronary angiography for stable or acute coronary disease presentations and eligible for percutaneous coronary intervention (PCI) will undergo intravascular imaging, including standard-of-care IVUS and then OCT-NIRAF pullback imaging conducted during an iodinated contrast flush. Patients will be consented prior to catheterization. Participant characteristics such as age, sex, BMI, and current medication regimen will be recorded. Standard of care blood chemistry will be reviewed and lab values from the subject's electronic medical records will be input into the study's Case Report Form when available. A complete medical history and data regarding prescribed cardiac medications also be transcribed from the EMR into the CRF.

LUMISIGHT injection will occur 2-12 hours prior to intravascular imaging procedure. Coronary Angiography will be performed. For participants for whom coronary angiography provides a clinical indication for intravascular imaging or PCI without any exclusion criteria, 30 study participants will undergo intravascular imaging, including standard-of-care IVUS and then research study OCT-NIRAF pullback imaging, conducted during an iodinated contrast flush.

Intravascular imaging of the PCI target artery will be done prior to PCI unless the interventional cardiologist determines that intervention is required to deliver the imaging catheters. The other major coronary arteries may also be imaged by IVUS and OCT-NIRAF based on clinical assessment of the appropriateness of imaging by the interventional cardiologist.

03

Conditions studied

  • Cardiovascular Diseases
  • Coronary Artery Disease

Browse trials for

Keywords

  • Optical Coherence Tomography
  • NIRAF
  • Cardiovascular
  • CAD
04

In context

Coronary Artery Disease Reclassified

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

This study's planned enrollment of 70 is below the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.

Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.

Compared within Coronary Artery Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Arm 1:

Inclusion criteria

Inclusion Criteria:

  • Participants with stable CAD or acute coronary syndromes undergoing invasive coronary angiography in the MGH cardiac catheterization laboratory
  • Participant is eligible for PCI
  • Participants must be over the age of 18
  • Participant must be able to give
  • Women with must have a negative pregnancy test within seven days prior to the procedure

Exclusion criteria

Exclusion Criteria:

  • CLINICAL EXCLUSION CRITERIA:

    • Renal insufficiency (GRF\<45 ml/min/1.73m2)
    • Pregnancy
    • Acute myocardial infarction: Participants with ST elevation MI will be excluded for at least 72 hours post event. Participants with non-ST elevation MI will be excluded if they have evidence of ongoing ischemia defined as chest pain or new changes in the previous 12 hours and/or rising cardiac biomarker enzymes (e.g., troponin or CKMB)
    • Evidence of ongoing or active clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure with systolic blood pressure \<90 mmHg, and severe congestive heart failure ( III or IV) or acute pulmonary edema,
    • Emergent procedures
    • \<= 35%
    • bleeding within the past 14 days
    • Any active, serious, life-threatening disease with a of less than 12 months
    • Inability to be evaluated at follow-up
    • Currently enrolled in another study utilizing OCT imaging, or in an trial that involves a non-approved cardiac drug or device
    • Participants under the protection of justice, guardianship, or curatorship

CARDIAC CATHETERIZATION LABORATORY - EXCLUSION CRITERIA (AFTER DIAGNOSTIC CORONARY ANGIOGRAM):

  • Participant deemed not indicated for intravascular imaging or PCI
  • Inability to perform intravascular imaging of a target artery
  • Left main disease >= 50% stenosis in participants that do not have a functioning LAD bypass graft
  • Clinical instability that develops after IVUS imaging but prior to OCT-NIRAF imaging

Arm 2: Because of the additional injection of LUMISIGHT, the following exclusion criteria (in addition to the criteria above) will be added:

ADDITIONAL EXCLUSION CRITERIA:

  • Renal insufficiency (GRF \<60 ml/min /1.73m2 )
  • History of to pegulicianine
  • History of allergic reaction to oral or intravenous contrast agents
  • History of allergic reaction to polyethylene glycol (PEG)
  • History of any documented allergic or anaphylactic reactions i.e to drugs or food (eggs, shellfish etc.) or chemicals (rubber, latex etc.) or other clinically significant allergies
  • Patients who have taken an investigational drug within 14 days of enrollment
  • Patients with uncontrolled hypertension defined as persistent systolic blood pressure > 180 mm Hg, or diastolic blood pressure > 110 mm Hg; those subjects with known HTN should be under these values while under pharmaceutical therapy
  • Severe concurrent illnesses including, but not limited to ongoing or major or severe active infections, symptomatic congestive heart failure, or asthma requiring hospitalization within the past 12 months, or psychiatric illness/social situations that would limit compliance with study requirements.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

06

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Participants with stable CAD or acute coronary syndromes undergoing invasive coronary angiography

    Participants referred to the Cardiology Division of the Massachusetts General Hospital, undergoing coronary angiography for stable or acute coronary disease and eligible for percutaneous coronary intervention (PCI) will be eligible for the study.

    Device: OCT-NIRAF

  • Experimental
    LUMISIGHT Injection

    Patients undergoing coronary angiography for stable or acute coronary disease presentations and eligible for percutaneous coronary intervention (PCI) will be imaged with OCT-NIRF following injection of LUMISIGHT . The primary objective of Arm 2 is to assess the feasibility of intravascular detection and spatial localization of LUMISIGHT - derived near-infrared fluorescence during routine coronary imaging.

    Drug: LUMISIGHT Injection · Device: OCT-NIRAF following LUMISIGHT Injection

Interventions

  • DeviceOCT-NIRAF

    Subjects will be imaged with OCT-NIRAF research catheter during their clinically indicated coronary angiogram. In addition, the subject will also receive two Coronary Computed Tomography Angiography (CCTA) 12 months apart, and images will be analyzed.

  • DrugPegulicianineStudies of PegulicianinePegulicianine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Up to 30 subjects will receive a single intravenous dose of LUMISIGHT administered 2-12 hours prior to their standard-of-care coronary procedure and experimental intravascular imaging.

  • DeviceOCT-NIRAF following LUMISIGHT Injection

    Subjects will be imaged with OCT-NIRAF research catheter during their clinically indicated coronary angiogram.

07

What researchers measure

Primary outcomes

  1. Plaque size estimation using OCT-NIRAF

    Optically derived signatures (OCT-NIRAF) will be compared to plaque volume measured by CCTA at baseline.

    Time frame: Data will be analyzed within 1 year after the procedure.

  2. Plaque progression estimate using OCT-NIRAF

    Changes in plaque volume will be measured by CCTA at baseline and after 1 year. Optically derived signatures (OCT-NIRAF) obtained at baseline will be compared to changes in plaque volume.

    Time frame: Data will be analyzed within 1 year after the procedure.

  3. Feasibility of using LUMISIGHT/Pegulicianine NIRF to detect the inflammation-driven fluorescence

    The feasibility of using LUMISIGHT/Pegulicianine NIRF to detect the inflammation-driven fluorescence recorded via OCT-NIRAF catheters.

    Time frame: Data will be analyzed within 1 year after the procedure.

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Apr 2028, 45 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 45 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Apr 2027 → Apr 2028 and completion Apr 2028 → Apr 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2024
First posted
Apr 18, 2024
StartActual
Jul 8, 2024
Primary completionEst.
Apr 30, 2028was Apr 2027
CompletionEst.
Apr 30, 2029was Apr 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 30, 2027→Apr 30, 2028
Nov 10, 2026
Study completion
Apr 30, 2028→Apr 30, 2029
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Apr 30, 2027→Apr 30, 2028
    Study completion Apr 30, 2028→Apr 30, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06374498
Responsible party
Guillermo Tearney (Professor of Pathology, Massachusetts General Hospital) — Principal investigator
First posted
Apr 18, 2024
Start date
Jul 8, 2024
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Guillermo J Tearney, MD, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegulicianine

Start the discussion